Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open‑market sale of 4,800 shares of common stock on February 27, 2026 under a pre‑arranged Rule 10b5‑1 plan adopted on August 18, 2025. The weighted average sale price was $25.1096 per share, with individual trades ranging from $25.00 to $25.325. After this transaction, she and her spouse jointly hold 109,843 shares, including 21,269 restricted stock units from a March 13, 2024 grant, 20,300 restricted stock units from a March 26, 2025 grant, and 22,000 restricted stock units from a February 20, 2026 grant, plus 19,200 shares held jointly.

Insider Trade Summary

Net Seller: 4,800 shares ($120,526)

Net Sell 1 txn

Insider Cvijic Christine Mikail

Role President and CFO

Sold 4,800 shs ($121K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,800	$25.1096	$121K

Holdings After Transaction: Common Stock — 109,843 shares (Direct)

Footnotes (1)

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 05:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cvijic Christine Mikail

(Last)

(First)

(Middle)

C/O NEUROGENE INC.

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK

10011

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		S⁽¹⁾		4,800	D	$25.1096⁽²⁾	109,843	D⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

Remarks:

	/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Neurogene Inc. (NGNE) report for Christine Mikail Cvijic?

Neurogene’s President and CFO, Christine Mikail Cvijic, reported selling 4,800 common shares. The sale occurred on February 27, 2026, as an open‑market transaction executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on August 18, 2025.

At what price were the Neurogene Inc. (NGNE) shares sold in this Form 4?

The reported weighted average sale price was $25.1096 per share. Individual trades took place in multiple transactions at prices ranging from $25.00 to $25.325, as disclosed, with full price‑by‑trade detail available upon request from the company or regulators.

How many Neurogene Inc. (NGNE) shares does Christine Mikail Cvijic own after the sale?

Following the sale, Christine Mikail Cvijic and her spouse jointly hold 109,843 shares. This total includes both directly held common stock and multiple tranches of restricted stock units that vest annually over future dates specified in the disclosure.

Was the Neurogene Inc. (NGNE) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed under a Rule 10b5‑1 trading plan. That plan was adopted by the reporting person on August 18, 2025, allowing pre‑scheduled sales independent of day‑to‑day market or personal timing decisions.

What restricted stock units does the Neurogene Inc. (NGNE) CFO hold after this transaction?

She holds 21,269 restricted stock units from a March 13, 2024 grant, 20,300 units from a March 26, 2025 grant, and 22,000 units from a February 20, 2026 grant, all vesting in equal annual installments on specified future anniversary dates.

How many Neurogene Inc. (NGNE) shares are held jointly by the CFO and her spouse?

The disclosure notes that 19,200 of the remaining shares are held jointly by the reporting person and her spouse, David Cvijic. These jointly held shares are separate from the unvested restricted stock units also included in her reported ownership.